Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland
Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR <i>E. coli<...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/11/12/1508 |
| _version_ | 1797455799169056768 |
|---|---|
| author | Patrycja Zalas-Więcek Katarzyna Płachta Eugenia Gospodarek-Komkowska |
| author_facet | Patrycja Zalas-Więcek Katarzyna Płachta Eugenia Gospodarek-Komkowska |
| author_sort | Patrycja Zalas-Więcek |
| collection | DOAJ |
| description | Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR <i>E. coli</i> isolates derived from clinical samples of hospitalized patients. Disk diffusion (DD) and MIC (minimum inhibitory concentration) test strip (MTS) methods were used. The results were interpreted based on EUCAST (version 12.0 2022) recommendations. Among all <i>E. coli</i> isolates, 98 (94.2%) and 99 (95.2%) were susceptible to CFDC when the DD and MTS methods were used, respectively (MIC range: <0.016–4 µg/mL, MIC<sub>50</sub>: 0.19 µg/mL, MIC<sub>90</sub>: 0.75 µg/mL). With the DD and MTS methods, all (MIC range: 0.016–2 µg/mL, MIC<sub>50</sub>: 0.19 µg/mL, MIC<sub>90</sub>: 0.75 µg/mL) but three (96.6%) ESBL-positive isolates were susceptible to CFDC. Out of all the metallo-beta-lactamase-positive <i>E. coli</i> isolates (MIC range: 0.016–4 µg/mL, MIC<sub>50</sub>: 0.5 µg/mL, MIC<sub>90</sub>: 1.5 µg/mL), 16.7% were resistant to CFDC with the DD method, while 11.1% were resistant to CFDC when the MTS method was used. CFDC is a novel therapeutic option against MDR and XDR <i>E. coli</i> isolates and is promising in the treatment of carbapenem-resistant <i>E. coli</i> strains, also for those carrying Verona integron-encoded metallo-beta-lactamases, when new beta-lactam-beta-lactamase inhibitors cannot be used. |
| first_indexed | 2024-03-09T15:59:01Z |
| format | Article |
| id | doaj.art-15a4253521a04e04b32e202215af2861 |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-09T15:59:01Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-15a4253521a04e04b32e202215af28612023-11-24T17:13:56ZengMDPI AGPathogens2076-08172022-12-011112150810.3390/pathogens11121508Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in PolandPatrycja Zalas-Więcek0Katarzyna Płachta1Eugenia Gospodarek-Komkowska2Department of Microbiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University (NCU) in Toruń, 85-094 Bydgoszcz, PolandDepartment of Microbiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University (NCU) in Toruń, 85-094 Bydgoszcz, PolandDepartment of Microbiology, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University (NCU) in Toruń, 85-094 Bydgoszcz, PolandCefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR <i>E. coli</i> isolates derived from clinical samples of hospitalized patients. Disk diffusion (DD) and MIC (minimum inhibitory concentration) test strip (MTS) methods were used. The results were interpreted based on EUCAST (version 12.0 2022) recommendations. Among all <i>E. coli</i> isolates, 98 (94.2%) and 99 (95.2%) were susceptible to CFDC when the DD and MTS methods were used, respectively (MIC range: <0.016–4 µg/mL, MIC<sub>50</sub>: 0.19 µg/mL, MIC<sub>90</sub>: 0.75 µg/mL). With the DD and MTS methods, all (MIC range: 0.016–2 µg/mL, MIC<sub>50</sub>: 0.19 µg/mL, MIC<sub>90</sub>: 0.75 µg/mL) but three (96.6%) ESBL-positive isolates were susceptible to CFDC. Out of all the metallo-beta-lactamase-positive <i>E. coli</i> isolates (MIC range: 0.016–4 µg/mL, MIC<sub>50</sub>: 0.5 µg/mL, MIC<sub>90</sub>: 1.5 µg/mL), 16.7% were resistant to CFDC with the DD method, while 11.1% were resistant to CFDC when the MTS method was used. CFDC is a novel therapeutic option against MDR and XDR <i>E. coli</i> isolates and is promising in the treatment of carbapenem-resistant <i>E. coli</i> strains, also for those carrying Verona integron-encoded metallo-beta-lactamases, when new beta-lactam-beta-lactamase inhibitors cannot be used.https://www.mdpi.com/2076-0817/11/12/1508carbapenemasescefiderocol<i>Escherichia coli</i>extended spectrum beta-lactamasesextensively drug-resistancemulti-drug-resistance |
| spellingShingle | Patrycja Zalas-Więcek Katarzyna Płachta Eugenia Gospodarek-Komkowska Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland Pathogens carbapenemases cefiderocol <i>Escherichia coli</i> extended spectrum beta-lactamases extensively drug-resistance multi-drug-resistance |
| title | Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland |
| title_full | Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland |
| title_fullStr | Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland |
| title_full_unstemmed | Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland |
| title_short | Cefiderocol against Multi-Drug and Extensively Drug-Resistant <i>Escherichia coli</i>: An In Vitro Study in Poland |
| title_sort | cefiderocol against multi drug and extensively drug resistant i escherichia coli i an in vitro study in poland |
| topic | carbapenemases cefiderocol <i>Escherichia coli</i> extended spectrum beta-lactamases extensively drug-resistance multi-drug-resistance |
| url | https://www.mdpi.com/2076-0817/11/12/1508 |
| work_keys_str_mv | AT patrycjazalaswiecek cefiderocolagainstmultidrugandextensivelydrugresistantiescherichiacoliianinvitrostudyinpoland AT katarzynapłachta cefiderocolagainstmultidrugandextensivelydrugresistantiescherichiacoliianinvitrostudyinpoland AT eugeniagospodarekkomkowska cefiderocolagainstmultidrugandextensivelydrugresistantiescherichiacoliianinvitrostudyinpoland |